Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Intra-Cellular Therapies (ITCI) Stock Price & Analysis
804 Followers
ITCI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$45.50 - $84.89
Previous Close$74.01
Volume658.78K
Average Volume (3M)973.40K
Market Cap
$7.72B
Enterprise Value$7.25B
Total Cash (Recent Filing)$493.02M
Total Debt (Recent Filing)$17.48M
Price to Earnings (P/E)-50.8
Beta0.49
Next Earnings
May 08, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding96,807,191
10 Day Avg. Volume2,214,564
30 Day Avg. Volume973,401
Standard Deviation0.36
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)12.11
Price to Sales (P/S)80.56
Price to Cash Flow (P/CF)-869.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.27
Enterprise Value/Gross Profit28.95
Enterprise Value/Ebitda-44.59
Forecast
1Y Price Target
$94.46Price Target Upside30.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Intra-Cellular Therapies News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsLumateperone achieved statistical significance at the earliest-tested timepoint and maintained that through the study, indicating strong potential as a treatment for major depressive disorder (MDD).
Financial PerformanceCaplyta's performance in approved indications was solid with robust sales figures, reflecting the drug's successful commercial execution and market acceptance.
Market PotentialAnalyst increases the probability of success to 95% for Caplyta based on supportive MDD data, highlighting the drug's potential to capture significant market share in the MDD space.
Bears Say
Legal ChallengesThe FDA recently disclosed receipt of numerous abbreviated new drug application filings for ITCI's Caplyta, potentially leading to costly litigation and delayed generic competition.
Management ChangesThe retirement of CFO Larry Hineline introduces uncertainty and a transitional period which may affect investor sentiment.
Market CompetitionOngoing generic challenges to Caplyta could impact its market exclusivity and long-term profitability.
---
Ownership Overview
32.26% Insiders
32.43% Mutual Funds
19.79% Other Institutional Investors
15.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $45.50 and its highest was $84.89 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Currently, no data Available
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is May 08, 2024 which is in 12 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on Feb 22, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.451 by $0.151.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -$0.32.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 104,327,130 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.451. Following the earnings report the stock price went down -1.842%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Among the largest hedge funds holding Intra-Cellular Therapies’s share is Perceptive Advisors LLC. It holds Intra-Cellular Therapies’s shares valued at 8M.
---
Intra-Cellular Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.46 (30.96% Upside)
$94.46 (30.96% Upside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $741.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.46%
12-Months-Change
Fundamentals
Return on Equity
-22.39%
Trailing 12-Months
Asset Growth
-3.51%
Trailing 12-Months
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
---
ITCI Earnings Call
Q4 2024
0:00 / 0:00
---
ITCI Stock 12 Months Forecast
Average Price Target
$94.46
▲(30.96% Upside)
Technical Analysis
Best Analysts Covering ITCI
1 Year
1 Year Success Rate
22/23 ratings generated profit
1 Year Average Return
+31.40%
reiterated a buy rating 9 days ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +31.40% per trade.
---